Biologics are genetically engineered proteins which originate from human genes. These drugs target the specific parts of the immune system. Biologics are entirely different from chemically synthesized drugs.
There is wide range of biologics products include vaccines, blood components, allergenic, somatic cells, gene therapy and recombinant therapeutic proteins. Biologics are constituted as nucleic acids or proteins or may be cells and tissue from living entities.
Biologics are isolated from different sources such as animal, human or microbes by using different biotechnological methods. Biologics are a complex mixture, and it is heat sensitive product and highly susceptible to microbial contamination. Therefore manufacturing of biologics needs very aseptic environment and skilled professional.
Hence, the demand for biologic contract manufacturing has shown subsequent growth. The pharmaceutical companies are signing an agreement with CMO’s for the manufacturing of biologics.
Request Sample PDF Brochure:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-2679
Biologics Contract Manufacturing Market: Drivers and Restraints
The factors driving the growth of biologics contract manufacturing are growing number of drug development by traditional pharmaceutical companies and the entrance of various small manufacturers in the pharmaceutical market.
Increasing rate of drug approval by FDA and number drugs in the pipeline has also boosted the growth of biologic contract manufacturing market. Increase in generic drugs competition and rise in patent expiry has also propelled the growth of biologics contract manufacturing market.
Increasing geriatric population and increasing the prevalence of diseases such as cancer are driving the growth of biologic contract manufacturing market. Production of biologics requires highly skilled professional and aseptic environment which will restrain the growth of this market. Beside that production of biologics are very complex and costly method which can again hamper the growth of this market.
Biologics Contract Manufacturing Market: Overview
Biologics contract manufacturing is expected to show significant growth over the forecast period. Biologics cover around 10-15% of revenue from overall revenue generated by leading pharmaceutical companies. Biologics contract manufacturing market is expected to show double growth in every five years.
This market is growing because of traditional pharmaceutical companies are unable for meet the need required for the production of biologics, besides that they are also the lack of skilled professional. Biologic contract manufacturing market can be classified by product type and indication.
On the basis on product type biologic contract manufacturing market is classified as antisense, gene therapy, cell therapy, growth factors, interferon’s, monoclonal antibodies, recombinant hormones, RNA interference, vaccines and others. From all product type monoclonal antibodies is expected to dominate the biologic contract manufacturing market.
Inquire Before Buying Research Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-2679
Biologics Contract Manufacturing Market: Regional Overview
Region-wise contract manufacturing market is classified as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America is expected to dominate the biologics contract manufacturing due to rise in FDA approval in last decade. Western Europe and Asia-Pacific then follow this market.
Western Europe is projected to show subsequent growth due to the high availability of skilled professional for the production of biologics. Asia-Pacific region is expected to show the fastest growth over the forecast period owing to rise in the number of CMO’s.
Biologics Contract Manufacturing Market: Key Players
Some of the key players in biologics contract manufacturing market are Boehringer Ingelheim, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Rentschler Biotechnologie GmbH, Celonic AG, AutekBio Co. Ltd., WuXiAppTec, Kemwell Biopharma, Shasun Pharma, Intas Pharmaceuticals, Syngene, Piramal Pharma Solutions, AAIPharma Services, Alpax Pharmaceuticals, Cantab Biopharmaceuticals Ltd, 3P Biopharmaceuticals, and BIBITEC GmbH.
Read Related Reports:
https://synkretic.mn.co/posts/24051778?utm_source=manual
https://synkretic.mn.co/posts/24051778?utm_source=manual
https://wecanchat.mn.co/posts/24051780?utm_source=manual
https://bipolarjungle.mn.co/posts/24051784?utm_source=manual
https://www.launchora.com/story/injectable-drug-delivery-market-trends-size-shar
About FMI
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 6-years.
Contact Us:
Future Market Insights
Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Report URL:
LinkedIn| Twitter| Blogs